Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

About the Center for Chronic Lymphocytic Leukemia

  • The Center for Chronic Lymphocytic Leukemia, part of the Hematologic Oncology (Blood Cancers) Treatment Center at Dana-Farber Brigham Cancer Center, promotes a comprehensive approach to the treatment of patients with chronic lymphocytic leukemia (CLL).

    Our program is one of only a few dedicated CLL centers in the country. Our team of specialists has unique expertise in caring for patients with this kind of cancer, including extensive prognostic testing, tissue banking, and access to cellular therapies including stem cell/bone marrow transplant and CAR T-cell therapy, if necessary.

    We are also a centralized hub for CLL research. Our team of laboratory and clinical-based investigators and physicians offers access to clinical trials of new, promising therapies. Our goal is to have a clinical trial option for patients at every stage of the disease. We offer clinical trials for newly-diagnosed CLL, relapsed/refractory CLL, as well as Richter's syndrome, a condition where CLL turns into an aggressive form of lymphoma.

    Patients may access a comprehensive range of services specialized for CLL treatment, including:

    From the time of diagnosis, Dana-Farber offers a personalized CLL risk-assessment, which provides detailed, patient-specific information about an individual's disease and prognosis. Our CLL experts use this information to plan and implement treatment strategies. We offer patients many CLL clinical trials, which give patients the opportunity to receive novel therapies. Our ultimate research goal is to improve current therapies to benefit all patients.

  • Jennifer R. Brown, MD, PhD, highlights available frontline therapies for chronic lymphocytic leukemia and factors that impact her preference for treatment.

  • New Patient Appointments

    Make Appointment Online
    Dana-Farber Brigham Cancer Center logo
    US News adult badge - smaller
  • Matthew Davids, MD, MMSc, on Advances in CLL Treatment
    Matthew Davids, MD, MMSc, of Dana-Farber’s Center for Chronic Lymphocytic Leukemia, shares updates on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients.

  • Services and Support at Dana-Farber

    new patient coordinators

    Becoming a Patient

    As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.

    cover supportive resources brochure

    Support Services and Amenities

    We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences.

    patient rating stars

    How Our Patients Rate Dana-Farber

    See patient satisfaction survey results for different Dana-Farber locations collected by Press Ganey, an independent company experienced in patient satisfaction surveying.

  • leukemia cells

    Rapid Heme Panel: A Major Advance in Blood Cancer Testing

    Physicians at Dana-Farber Brigham Cancer Center have begun using Rapid Heme Panel, a high-tech genetic test that provides, within a matter of days, critical information to aid the choice of treatment.
    Blum Center creative arts program participant

    The Eleanor and Maxwell Blum Patient and Family Resource Center

    The Blum Resource Center provides patients and family members with a comfortable environment to learn more about disease treatment and management.

    healthy smoothies

    Eating Well During Cancer Video Series

    This video series and resource toolkit features Dana-Farber nutrition specialist Stacy Kennedy, MPH, RD, CSO, LDN, and explores how diet can help support your health and wellbeing during and after cancer treatment.